ArticleFEBS open bio2018
Plasma anti-BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer.
Article in FEBS open bio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 113 citations in OpenAlex.
- The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer.BMC pulmonary medicine · 2024Article
- Efficacy of immune checkpoint inhibitors along with chemotherapy in non-small cell lung cancer and the impact on adverse reactions and serum tumor markers.American journal of translational research · 2023Article
- Development of a prognostic model of glioma based on immune-related genes.Oncology letters · 2021Article
- Clinical value of seven autoantibodies combined detection in the diagnosis of lung cancer.Journal of clinical laboratory analysis · 2020Article
- Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.FEBS open bio · 2020Article
- Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for non‑small cell lung cancer.Oncology reports · 2020Article
- MGMT autoantibodies as a potential prediction of recurrence and treatment response biomarker for glioma patients.Cancer medicine · 2019Article
- Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis.Disease markers · 2019Article
- Circulating anti-p16a IgG autoantibodies as a potential prognostic biomarker for non-small cell lung cancer.FEBS open bio · 2018Article
- Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.Scientific reports · 2018Article
- Circulating natural antibodies to inflammatory cytokines are potential biomarkers for atherosclerosis.Journal of inflammation (London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent study demonstrated that circulating levels of IgG antibodies against linear peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) were significantly increased in nonsmall cell lung cancer (NSCLC). This study was undertaken to replicate this initial work in an independent sample. An enzyme-linked immunosorbent assay (ELISA) was developed in-house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC5a, BIRC5b, and MYC in 211 patients with NSCLC and 200 control subjects. A Mann-Whitney
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.